Abstracts Archive - Page 119 of 1683 - ATC Abstracts

2022 American Transplant Congress
Lung Transplantation For COVID Acute Respiratory Distress Syndrome: A Pediatric And Adult Case Series
C. Arendale¹, D. Kumar², P. S. Garcha³, C. Kutac⁴, G. Loor¹, A. Rana¹, J. Goss¹, N. Galvan¹
¹Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, ²Department of Biochemistry, Baylor College of Medicine, Houston, TX, ³Department of Medicine, Baylor College of Medicine, Houston, TX, ⁴Baylor St. Luke’s Medical Center, Houston, TX
*Purpose: Lung transplantation (LTx) has been shown to be a viable treatment for irreversible lung disease caused by COVID-19. Given the limited data on the…
2022 American Transplant Congress
Safety and Efficacy of GLP-1 Agonists in Solid Organ Transplant Recipients
E. Heiman, D. Blanco, A. Webb
Pharmacy, Tampa General Hospital, Tampa, FL
*Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have been shown to improve glycemic control, obesity, and cardiovascular disease in the general population. The safety and…
2022 American Transplant Congress
Validation of the PROMIS® Medication Adherence Scale Among Kidney Transplant Recipients on Tacrolimus
J. D. Peipert¹, R. Slay², B. Smith², D. Cella¹, A. Keys², D. Taber²
¹Northwestern University, Chicago, IL, ²Medical University of South Carolina, Charleston, SC
*Purpose: Kidney transplant recipients (KTR) take a daily regimen of immunosuppression medication that almost inevitably includes tacrolimus (TAC). Non-adherence to TAC is a strong predictor…
2022 American Transplant Congress
Humoral Response After a Third Dose of Sars-CoV-2 mRNA Vaccine in Transplant Recipients
A. E. Woolley, N. Sharma, G. Zhou, A. Kim, E. Ryan, M. Joyce, H. Goldberg, M. Givertz, M. Mehra, E. Woodcome, V. Durney, S. Marshall, K. Townsend, A. Coppolino, S. Tullius, S. Malek, H. Mallidi, L. Baden, A. Chandraker
Brigham & Women's Hospital, Boston, MA
*Purpose: Prior studies demonstrated an increased immune response post-3rd COVID-19 vaccine dose when given 1-month post-2nd dose in solid organ transplant recipients (SOT). This study…
2022 American Transplant Congress
Patient Preferences for Waiting Time and Kidney Quality: A Discrete Choice Experiment
S. Mehrotra
Industrial Engineering and Management Sciences, Northwestern University, Evanston, IL
*Purpose: The purpose of this study was to elicit patient preferences involving tradeoffs between a lower quality kidney offered today and a higher quality, future…
2022 American Transplant Congress
Transplant Combined with Neoadjuvant Therapy Improves Survival for Patients with Liver-Limited, Locally Advanced Intrahepatic Cholangiocarcinoma: A SEER Database Analysis
G. G. Panayotova¹, M. Javle², S. Pentakota¹, F. Paterno¹, A. Amin¹, L. Brown¹, S. Simonishvili¹, Y. Qin¹, T. Ayorinde¹, G. Prakash¹, C. Conrad³, J. V. Guarrera¹, K. E. Lunsford¹
¹Rutgers New Jersey Medical School, Newark, NJ, ²University of Texas, MD Anderson Cancer Center, Houston, TX, ³St. Elizabeth's Medical Center, Boston, MA
*Purpose: Preliminary single-center data suggest multimodal therapy may improve outcomes for patients with intrahepatic cholangiocarcinoma (iCCA) undergoing liver transplant (LT), particularly in the setting of…
2022 American Transplant Congress
Rapid Formalin-Fixed Deceased Donor Kidney Biopsy Protocol – A Proof Of Concept
M. R. Marvin¹, G. Chen², A. Kotru¹, C. Koo¹, P. Sanghi³, M. Moritz⁴, J. Clarke⁴, R. Hasz⁴
¹Transplant, Geisinger Medical Center, Danville, PA, ²Pathology, Geisinger Medical Center, Danville, PA, ³Transplant Nephrology, Geisinger Medical Center, Danville, PA, ⁴Gift of Life Donor Program, Philadelphia, PA
*Purpose: Reducing kidney discard is a major priority for the transplant community. While frozen section biopsies are the current standard, they are fraught with technical…
2022 American Transplant Congress
Comparing The Immunologic Responses Between Kidney Transplant Recipients Receiving Standard Immunosuppression And CNI Reduction After Two Doses Of ChAdOx-1 And A Booster Dose BNT162b2
S. Phirom¹, T. Kitrungphaiboon², W. Jantarabenjakul², Y. Avihingsanon², W. Prasithsirikul³, J. Vanichanan⁴, P. Hansasuta⁵, N. Townamchai⁶
¹Nephrology division, Department of medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand, ²King Chulalongkorn Memorial Hospital, Bangkok, Thailand, ³Bamrasnaradura infectious disease institute, Bangkok, Thailand, ⁴Infectious diseases, Department of medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand, ⁵Department of Microbiology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand, ⁶Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand
*Purpose: Immunosuppression can impair immunological responses after vaccination in kidney transplant recipients (KTR). However, little is known about the effect of the booster dose of…
2022 American Transplant Congress
Barriers and Facilitators to Care for Patients with Failed Kidney Transplants
A. Huml¹, K. Berg², A. Perzynski², C. Sullivan², A. Sehgal²
¹Department of Kidney Medicine, Cleveland Clinic, Cleveland, OH, ²Population Health Research Institute, The MetroHealth System, Cleveland, OH
*Purpose: To understand the barriers and facilitators to care for patients with failed kidney transplants from the perspective of providers.*Methods: Qualitative study employed focus groups…
2022 American Transplant Congress
Post-Kidney Transplant Valacyclovir versus Valganciclovir for CMV Prophylaxis: A Randomized Controlled Trial
P. S. Verghese¹, A. Matas², S. Chinnakotla², M. Evans³, H. Balfour Jr⁴
¹Univ of Minnesota Pediatric Nephrology, Minneapolis, MN, ²Surgery, University of Minnesota Medical School, Minneapolis, MN, ³Biostatistics, University of Minnesota, Minneapolis, MN, ⁴Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN
*Purpose: Valganciclovir (valG) is an effective CMV prophylactic agent post-kidney transplant (KTx) with significant side effects. Valacyclovir (valA) may be effective for CMV prophylaxis with…